Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors

This study is testing whether adding an immunotherapy drug called serplulimab to standard radiation and chemotherapy (chemoradiotherapy) improves outcomes in women with early-stage cervical cancer who have risk factors for recurrence after surgery. **You may be eligible if...** - You are a woman aged 18 to 65 - You have confirmed cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) - Your cancer is early-to-intermediate stage (FIGO IB1, IB2, IIA1, or IIA2) - You had a full radical hysterectomy and pelvic lymph node removal - After surgery, pathology showed at least 2 high-risk features (e.g., lymph node spread, positive margins, deep invasion, or lymphovascular invasion) - Your tumor tested positive for PD-L1 (a marker that predicts immunotherapy response) - You are in good general health and your blood counts and organ function are normal **You may NOT be eligible if...** - You have remaining tumor that could not be removed - You have rare cervical cancer types (small cell neuroendocrine or mucinous adenocarcinoma) - You had prior pelvic radiation - You have an active autoimmune disease or are on steroids/immunosuppressants - You had a blood clot event in the past 6 months - You have serious heart disease Talk to your doctor to see if this trial is right for you.